SRSF2 mutations are found commonly in ~50% of CMML, ~15% of MDS, ~20% of s‐AML patients, and are often associated with poor prognosis and a higher risk of transformation to acute leukemia.26, 51, 68, 69 SRSF2 is a member of the serine/arginine‐rich (SR) family of proteins that recognizes specific RNA motifs, and is generally a positive regulator of exon inclusion.70 Somatic mutations in SRSF2 are restricted to the P95 amino acid residue near the RNA recognition motif. Here, SRSF2 is linked to chronic myelomonocytic leukemia.